Biotek-snakken — Juni 2020
-
During an investor call earlier this week, Baselga played down concerns there could be read across here from gastric to breast cancer and said his views on potentially establishing Enhertu in a broader cohort of breast cancer patients are unchanged, largely on the strength of extensive data AstraZeneca has seen in this setting.
-
-
Fate i emi - var det ikke Solsen, som nappede en bid? Fate expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. https://finance.yahoo.com/news/fate-therapeutics-announces-proposed-public-200110051.html
-
-
Så køre toget
SUTRO med nye data på STRO-002 den 22. juni.https://www.sutrobio.com/sutro-biopharma-to-present-new-preclinical-data-on-its-stro-002-antibody-drug-conjugate-at-the-upcoming-aacr-2020-virtual-meeting-on-june-22-2020/ -
Forstår ikke hvorfor Saniona stadig roder rundt i niveauet 26-27 SEK, men det bliver der nok lavet om på, når Tesofensine bliver godkendt i Mexico indenfor 1-2 mdr og Tesomet rykker over i fase III i løbet af efteråret.......så taler vi kurs 50-60 SEK som minimum.
-
@Mcjean - tror du ikke bare det bliver en snik-snak...han er blevet lidt forsigtig med at spå
Tror først der kommer mere kød på i slutningen af året ifbm. SITC og ASH i november og december....det er hvad der er meldt ud. Og så er der vel 1 måned eller 2 endnu inden vi hører om resultatet af "fast track" på ACCORD-2 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind